Birdwatch Note
2025-01-02 23:23:20 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
While the small Stanford study's findings are promising, ibogaine is currently classified as a Sched I controlled substance in the US, indicating it is not approved for medical use due to concerns about safety, including cardiac arrest and sudden death risks https://www.smithsonianmag.com/smart-news/a-lesser-known-psychedelic-drug-shows-promise-for-ptsd-treatment-180983556/ https://www.nature.com/articles/s41467-024-51856-y#:~:text=The%20use%20of%20ibogaine%20has,both%20ibogaine%20and%20noribogaine37 https://journals.sagepub.com/doi/full/10.1177/2045125315626073
Written by F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1874909583354790303
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1874959694537597396
- noteId - 1874959694537597396
- participantId -
- noteAuthorParticipantId - F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D Participant Details
- createdAtMillis - 1735860200901
- tweetId - 1874909583354790303
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- While the small Stanford study's findings are promising, ibogaine is currently classified as a Sched I controlled substance in the US, indicating it is not approved for medical use due to concerns about safety, including cardiac arrest and sudden death risks https://www.smithsonianmag.com/smart-news/a-lesser-known-psychedelic-drug-shows-promise-for-ptsd-treatment-180983556/ https://www.nature.com/articles/s41467-024-51856-y#:~:text=The%20use%20of%20ibogaine%20has,both%20ibogaine%20and%20noribogaine37 https://journals.sagepub.com/doi/full/10.1177/2045125315626073
Note Ratings
| rated at | rated by | |
| 2025-01-03 22:54:24 -0600 | Rating Details | |
| 2025-01-03 12:50:20 -0600 | Rating Details | |
| 2025-01-03 04:23:58 -0600 | Rating Details | |
| 2025-01-02 19:53:54 -0600 | Rating Details | |
| 2025-01-02 19:48:57 -0600 | Rating Details | |
| 2025-01-02 19:47:20 -0600 | Rating Details | |
| 2025-01-02 19:35:07 -0600 | Rating Details | |
| 2025-01-02 19:30:09 -0600 | Rating Details | |
| 2025-01-02 19:22:38 -0600 | Rating Details | |
| 2025-01-02 19:21:11 -0600 | Rating Details | |
| 2025-01-02 19:15:24 -0600 | Rating Details | |
| 2025-01-02 19:12:29 -0600 | Rating Details | |
| 2025-01-02 19:03:26 -0600 | Rating Details | |
| 2025-01-02 17:45:26 -0600 | Rating Details | |
| 2025-01-05 03:59:05 -0600 | Rating Details | |
| 2025-01-03 08:31:25 -0600 | Rating Details | |
| 2025-01-03 08:22:16 -0600 | Rating Details | |
| 2025-01-03 07:51:47 -0600 | Rating Details | |
| 2025-01-02 21:55:08 -0600 | Rating Details | |
| 2025-01-02 21:02:10 -0600 | Rating Details | |
| 2025-01-02 20:28:21 -0600 | Rating Details | |
| 2025-01-02 20:26:06 -0600 | Rating Details | |
| 2025-01-02 20:25:38 -0600 | Rating Details | |
| 2025-01-02 19:44:37 -0600 | Rating Details | |
| 2025-01-02 19:41:13 -0600 | Rating Details | |
| 2025-01-02 19:36:56 -0600 | Rating Details | |
| 2025-01-02 19:12:09 -0600 | Rating Details | |
| 2025-01-02 18:56:05 -0600 | Rating Details | |
| 2025-01-02 18:18:44 -0600 | Rating Details | |
| 2025-01-02 17:37:00 -0600 | Rating Details | |
| 2025-01-02 17:33:32 -0600 | Rating Details | |
| 2025-01-03 13:53:26 -0600 | Rating Details | |
| 2025-01-03 07:54:12 -0600 | Rating Details | |
| 2025-01-03 06:40:25 -0600 | Rating Details | |
| 2025-01-03 02:20:13 -0600 | Rating Details | |
| 2025-01-03 01:42:51 -0600 | Rating Details | |
| 2025-01-03 00:51:48 -0600 | Rating Details | |
| 2025-01-02 21:52:40 -0600 | Rating Details | |
| 2025-01-02 21:52:28 -0600 | Rating Details | |
| 2025-01-02 20:57:27 -0600 | Rating Details | |
| 2025-01-02 20:25:26 -0600 | Rating Details | |
| 2025-01-02 20:21:30 -0600 | Rating Details | |
| 2025-01-02 20:06:24 -0600 | Rating Details | |
| 2025-01-02 19:52:11 -0600 | Rating Details | |
| 2025-01-02 19:33:58 -0600 | Rating Details | |
| 2025-01-02 19:29:18 -0600 | Rating Details | |
| 2025-01-02 19:12:50 -0600 | Rating Details | |
| 2025-01-02 19:12:46 -0600 | Rating Details | |
| 2025-01-02 17:29:35 -0600 | Rating Details | |
| 2025-01-04 11:47:01 -0600 | Rating Details | |
| 2025-01-03 15:58:40 -0600 | Rating Details | |
| 2025-01-03 15:56:40 -0600 | Rating Details | |
| 2025-01-03 07:21:16 -0600 | Rating Details | |
| 2025-01-03 05:25:59 -0600 | Rating Details | |
| 2025-01-03 02:19:08 -0600 | Rating Details | |
| 2025-01-03 01:58:32 -0600 | Rating Details | |
| 2025-01-03 00:26:50 -0600 | Rating Details | |
| 2025-01-02 20:05:55 -0600 | Rating Details | |
| 2025-01-02 19:47:06 -0600 | Rating Details | |
| 2025-01-02 19:39:02 -0600 | Rating Details | |
| 2025-01-02 19:38:04 -0600 | Rating Details | |
| 2025-01-02 19:13:44 -0600 | Rating Details | |
| 2025-01-02 19:13:11 -0600 | Rating Details | |
| 2025-01-02 18:50:40 -0600 | Rating Details | |
| 2025-01-02 17:45:06 -0600 | Rating Details | |
| 2025-01-05 02:57:11 -0600 | Rating Details | |
| 2025-01-03 08:23:47 -0600 | Rating Details | |
| 2025-01-02 23:41:25 -0600 | Rating Details | |
| 2025-01-02 21:52:44 -0600 | Rating Details | |
| 2025-01-02 21:37:48 -0600 | Rating Details | |
| 2025-01-02 21:33:13 -0600 | Rating Details | |
| 2025-01-02 21:24:03 -0600 | Rating Details | |
| 2025-01-02 20:59:55 -0600 | Rating Details | |
| 2025-01-02 20:48:24 -0600 | Rating Details | |
| 2025-01-02 20:35:43 -0600 | Rating Details | |
| 2025-01-02 20:35:18 -0600 | Rating Details | |
| 2025-01-02 20:29:52 -0600 | Rating Details | |
| 2025-01-02 20:25:23 -0600 | Rating Details | |
| 2025-01-02 20:25:18 -0600 | Rating Details | |
| 2025-01-02 19:49:04 -0600 | Rating Details | |
| 2025-01-02 19:33:16 -0600 | Rating Details | |
| 2025-01-02 19:01:03 -0600 | Rating Details | |
| 2025-01-03 10:44:28 -0600 | Rating Details | |
| 2025-01-03 07:15:54 -0600 | Rating Details | |
| 2025-01-03 07:05:34 -0600 | Rating Details | |
| 2025-01-03 06:37:40 -0600 | Rating Details | |
| 2025-01-03 05:44:22 -0600 | Rating Details | |
| 2025-01-03 03:40:06 -0600 | Rating Details | |
| 2025-01-02 23:30:42 -0600 | Rating Details | |
| 2025-01-02 21:19:23 -0600 | Rating Details | |
| 2025-01-02 20:56:35 -0600 | Rating Details | |
| 2025-01-02 20:35:04 -0600 | Rating Details | |
| 2025-01-02 20:03:39 -0600 | Rating Details | |
| 2025-01-02 20:03:26 -0600 | Rating Details | |
| 2025-01-02 19:44:48 -0600 | Rating Details | |
| 2025-01-02 19:36:37 -0600 | Rating Details | |
| 2025-01-02 19:27:57 -0600 | Rating Details | |
| 2025-01-02 19:18:54 -0600 | Rating Details | |
| 2025-01-02 19:12:41 -0600 | Rating Details | |
| 2025-01-02 18:11:50 -0600 | Rating Details | |
| 2025-01-02 18:02:49 -0600 | Rating Details | |
| 2025-01-02 17:39:06 -0600 | Rating Details | |
| 2025-02-15 23:05:16 -0600 | Rating Details |